Tracy L. Rose, MD, on Clinical Implications of Treating Bladder Cancer With Neoadjuvant Gemcitabine, Cisplatin, and Pembrolizumab

Posted: Saturday, March 6, 2021

Tracy L. Rose, MD, of the University of North Carolina at Chapel Hill, discusses phase II study findings supporting the use of gemcitabine and split-dose cisplatin plus pembrolizumab as neoadjuvant therapy prior to radical cystectomy for patients with muscle-invasive bladder cancer. Dr. Rose offers urologic surgeons and medical oncologists suggestions for coordinating their efforts.